Canaccord Genuity Maintains Hold on Veracyte, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 85.1%

Neg 85.1% Neu 0% Pos 0%

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the price target from $43 to $40.